BSE Live
Mar 25, 16:01Prev. Close
87.39
Open Price
87.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Cash Flow of Godavari Drugs (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 12.81 | 13.83 | 10.81 | 11.57 | 10.24 | |
| Net CashFlow From Operating Activities | 11.20 | 18.41 | 13.22 | 11.23 | 1.33 | |
| Net Cash Used In Investing Activities | -19.51 | -13.22 | -8.64 | -4.97 | -1.25 | |
| Net Cash Used From Financing Activities | 8.07 | -5.65 | -3.77 | -5.62 | 0.13 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -0.25 | -0.46 | 0.81 | 0.64 | 0.21 | |
| Cash And Cash Equivalents Begin of Year | 2.62 | 3.08 | 2.28 | 1.64 | 1.43 | |
| Cash And Cash Equivalents End Of Year | 2.37 | 2.62 | 3.08 | 2.28 | 1.64 |
25.02.2026
Godavari Drugs Standalone December 2025 Net Sales at Rs 22.18 crore, down 24.93% Y-o-Y
24.11.2025
Godavari Drugs Standalone September 2025 Net Sales at Rs 26.65 crore, up 2.15% Y-o-Y
10.06.2025
Godavari Drugs Standalone March 2025 Net Sales at Rs 25.50 crore, down 34% Y-o-Y
17.02.2025
Godavari Drugs Standalone December 2024 Net Sales at Rs 29.55 crore, down 31.45% Y-o-Y
25.02.2026
Godavari Drugs Standalone December 2025 Net Sales at Rs 22.18 crore, down 24.93% Y-o-Y
24.11.2025
Godavari Drugs Standalone September 2025 Net Sales at Rs 26.65 crore, up 2.15% Y-o-Y
10.06.2025
Godavari Drugs Standalone March 2025 Net Sales at Rs 25.50 crore, down 34% Y-o-Y
17.02.2025
Godavari Drugs Standalone December 2024 Net Sales at Rs 29.55 crore, down 31.45% Y-o-Y
25.03.2026
25.03.2026
25.03.2026
24.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth